Bolster U.S. drug manufacturing to lower drug prices.

President Trump should take real steps to actually lower drug prices, including ... bolstering U.S. drug manufacturing...

Welch commits to strengthening U.S. drug manufacturing as a strategy to lower drug prices.

Welch Statement on Launch of TrumpRx
primary · press_release · model gpt-4.1

Restoring and bolstering American innovation.

Senate Democrats, including Welch, committed to restoring and bolstering American innovation in drug manufacturing as part of efforts to lower drug costs.

Welch, Senate Democrats Blast Trump’s Drug Pricing Fraud, Lay Out Agenda for Lower Prices | Senator Welch
secondary · other · model gpt-4.1

U.S. Senators Peter Welch and Amy Klobuchar reintroduced the Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act, legislation to expand Medicare negotiation of drug prices to lower drug costs for consumers, reduce federal spending, and give the U.S. Department of Health and Human Services (HHS) stronger tools to negotiate lower drug prices in Medicare Part B and Part D.

Senator Welch co-introduced the SMART Prices Act to enhance Medicare's ability to negotiate drug prices, aiming to lower costs for consumers and reduce federal spending.

partial same_term A for effort

Welch, Klobuchar Lead 25 Colleagues on Legislation to Expand Medicare Drug Price Negotiation and Lower Costs for Americans | Senator Welch
primary · model gpt-4.1 · confidence 0%

U.S. Senators Peter Welch, Josh Hawley, and Amy Klobuchar introduced the Eliminating Thickets to Improve Competition (ETHIC) Act, bipartisan legislation to streamline drug patent litigation, encourage fair market competition, and lower prescription drug prices by making it easier for generic and biosimilar companies to enter the market.

Senator Welch co-introduced the ETHIC Act to simplify drug patent litigation and promote competition, facilitating the entry of generics and biosimilars to lower drug prices.

partial same_term A for effort

Welch, Hawley, Klobuchar Introduce Bipartisan Legislation to Streamline Drug Patent Litigation, Lower Cost of Prescription Drugs
secondary · model gpt-4.1 · confidence 0%

U.S. Senator Peter Welch joined Senators Jeff Merkley, Bernie Sanders, and Representative Debbie Dingell in introducing the End Price Gouging for Medications Act, which would lower prescription drug costs for all Americans by requiring drug companies to offer medications in the United States at no more than the lowest price per drug in twelve other similarly developed countries.

Senator Welch co-introduced the End Price Gouging for Medications Act to cap U.S. drug prices at levels comparable to those in other developed countries.

partial same_term A for effort

Welch, Merkley, Sanders, Dingell Team Up to Introduce Bill to Lower Prescription Drug Prices for All Americans
secondary · model gpt-4.1 · confidence 0%

U.S. Senator Peter Welch led Senators Roger Marshall, Mark Warner, and Bill Cassidy in introducing the bipartisan Protecting Pharmacies in Medicaid Act, legislation to limit abusive pricing practices by pharmacy benefit managers (PBMs), including 'spread pricing,' which drives up costs for Medicaid and short-changes pharmacies.

Senator Welch co-introduced the Protecting Pharmacies in Medicaid Act to curb PBMs' pricing practices that increase Medicaid costs and harm pharmacies.

partial same_term A for effort

Welch, Marshall, Warner and Cassidy Lead Bipartisan Bill to Crack Down on PBMs’ Abusive Pricing Practices
secondary · model gpt-4.1 · confidence 0%

Senator Peter Welch issued a statement responding to Merck's lawsuit to block drug price negotiation provisions included in the Inflation Reduction Act, emphasizing his commitment to preserving these provisions and helping Vermonters afford prescription drugs.

Senator Welch opposed Merck's lawsuit against drug price negotiation provisions, reaffirming his dedication to lowering prescription drug costs.

partial same_term A for effort

Senator Peter Welch Responds to Big Pharma’s Efforts to Block Plan to Cut Drug Prices
secondary · model gpt-4.1 · confidence 0%

Senator Peter Welch highlighted the passage of the Inflation Reduction Act, which empowers Medicare to negotiate drug prices for the first time, as a significant step toward more government action to control health costs.

Senator Welch emphasized the Inflation Reduction Act's role in enabling Medicare to negotiate drug prices, marking progress in controlling health costs.

partial same_term A for effort

‘The slippery slope is powerful’: Dems believe drug pricing law will pay dividends
secondary · model gpt-4.1 · confidence 0%

CMS says the selected-drug file contains negotiated maximum fair prices, was updated with a ZIP file dated May 26, 2026, and includes information on selected drugs, NDCs, and negotiated prices. The page states that first-cycle maximum fair prices for 10 Part D drugs go into effect January 1, 2026, and that second-cycle prices go into effect January 1, 2027.

Latest official CMS implementation records show Medicare drug price negotiation is active and price files were updated shortly before the lookback window, but this is a drug-pricing implementation record rather than evidence of bolstered U.S. drug manufacturing.

partial same_term

Selected Drugs and Negotiated Prices | CMS
secondary · model gpt-5.5 · confidence 88%

CMS states that the Inflation Reduction Act gave Medicare the ability to directly negotiate prices for certain high-expenditure, single-source drugs without generic or biosimilar competition. CMS says negotiated prices for 10 Part D drugs go into effect January 1, 2026, and estimates $6 billion in net covered prescription drug savings and $1.5 billion in projected savings for Medicare Part D enrollees if the negotiated prices applied as described.

The strongest official delivery evidence is lower Medicare drug prices taking effect in 2026. It partially advances the lower-drug-prices goal but does not show delivery of the manufacturing-specific promise.

partial same_term

Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026
secondary · model gpt-5.5 · confidence 90%

The House Clerk records Roll Call 420 on H.R. 5376 as passed, 220 yeas to 207 nays, on the motion to concur in the Senate amendment. The roll call lists Welch, Democratic, Vermont, voting Yea.

Welch voted for the Inflation Reduction Act while serving in the House, supporting the law later used to implement Medicare drug price negotiation. This is concrete effort toward lower prices, not manufacturing-specific delivery.

partial unknown A for effort

Office of the Clerk, U.S. House of Representatives: Roll Call 420, H.R. 5376
secondary · model gpt-5.5 · confidence 86%

Congress.gov lists S.1836, the SMART Prices Act, sponsored by Sen. Amy Klobuchar and referred to the Senate Finance Committee on May 21, 2025. The tracker says the bill has the status Introduced and has not passed the Senate, House, gone to the President, or become law.

Welch-backed drug-pricing expansion legislation remained unresolved in Congress, showing serious effort but no enacted manufacturing or price-lowering delivery from this bill as of the record checked.

unresolved same_term A for effort

S.1836 - SMART Prices Act, 119th Congress (2025-2026) | Congress.gov
secondary · model gpt-5.5 · confidence 89%

Welch's Senate office says he introduced the bipartisan ETHIC Act with Senators Hawley and Klobuchar to streamline drug patent litigation, encourage fair market competition, and lower prescription drug prices by making it easier for generic and biosimilar companies to enter the market.

The ETHIC Act is a concrete Senate action to increase generic and biosimilar competition and lower prices. It is adjacent to drug manufacturing market entry but does not by itself prove bolstered U.S. manufacturing or enacted delivery.

partial same_term A for effort

Welch, Hawley, Klobuchar Introduce Bipartisan Legislation to Streamline Drug Patent Litigation, Lower Cost of Prescription Drugs
secondary · model gpt-5.5 · confidence 84%

Axios reported that Welch said he would support and work aggressively to pass a most-favored-nation drug pricing policy and that Welch and Sen. Josh Hawley were working on a bipartisan bill to bar drugmakers from charging Americans more than the international average price.

This is the most recent located post-assessment evidence of continued Welch activity on lowering drug prices, but it is reporting on intent and pending work, not official proof of manufacturing delivery.

partial same_term A for effort

Exclusive: Sen. Welch would back Trump's most-favored-nation drug policy plan
secondary · model gpt-5.5 · confidence 72%